




# La microcirculation en 2022

**Julien Adjedj**


**01/06/2022**

# Introduction: du syndrome X à l'INOCA



## Syndrome X coronaire



## INOCA






# Diagnostic et traitement









# Prévalence

## Non-invasive Methods



## Invasive Methods





# CLINICAL PERSPECTIVE

## What Is New?

- In patients with no obstructive coronary artery disease, approximately half of cases present with underlying disease, either coronary microvascular disease or coronary vasospasm.
- Coronary microvascular disease is more prevalent in female patients; nonetheless, male patients are affected in a significant proportion.
- Invasive and noninvasive diagnostic methods identified a similar proportion of patients with coronary microvascular disease.

## What Are the Clinical Implications?


- The large variability of methods, definitions, and thresholds for diagnosing coronary microvascular disease and coronary vasospasm is a call to a refinement and standardization of diagnostic tools.
- Greater awareness among physicians of ischemia with no obstructive coronary arteries is urgently needed for proper diagnosis and patient-tailored management.



Prevalence of coronary microvascular dysfunction.



# Méthodes de mesure




# Index of Microvascular Resistance (IMR)

Pressurewire® Abbott + Coroventis



# Microvascular Resistance Reserve

## CENTRAL ILLUSTRATION: Simultaneous Registration of Pressures, Temperature, and Flow Velocity in the Right Coronary Artery



**B**

$$Q = 1.08 \cdot \frac{T_i}{T} \cdot Q_i$$

$$R_{cr,rest} = P_d / Q_{rest}$$












$$R_{cr,hyper} = P_d / Q_{hyper}$$

$$MRR = \frac{Q_{hyper}}{Q_{rest}} \cdot \frac{P_{d,rest}}{P_{d,hyper}}$$






# Méthodes de mesure




# Résumé

Pressurewire  
+  
Coroventis



Débit max & Débit "repos"

Pressurewire  
+  
Rayflow  
+  
Coroventis







# Perspectives

## How was the study executed?


### An example of angio-IMR derivation



Pa = 93 mmHg → catheter  
 D = 58 mm → 3D-QCA  
 V = 22 cm/seg → Frame counting  
 QFR = 0.96 → FCA



$$\begin{aligned} \text{Angio-IMR} &= (Pa_{\text{rest}} - [0.1 \cdot Pa_{\text{rest}}]) \cdot cQFR \cdot (\text{length}/v) \\ \text{Angio-IMR} &= (93 - [0.1 \cdot 93]) \cdot 0.96 \cdot (0.058/0.22) \\ \text{Angio-IMR} &= 21 \text{ U} \end{aligned}$$

\* Mejia-Renteria et al. Catheter Cardiovasc Interv. 2021




# Perspectives


Correlation and agreement between angio-IMR and thermo-IMR



Diagnostic performance of angio-IMR



Accuracy of angio-IMR





# Thérapeutique

**Randomized  
151 Patients**



**Angina & No  
Obstructive CAD**

**Intervention**  
Invasive Coronary  
Function Guided  
Care (n=75)




**Control**  
Angiography guided  
Care (n=76)

**Linked Diagnosis:**  
Microvascular angina  
Vasospastic angina  
Non-cardiac



**Therapy:**  
Stratify Antianginals  
Non-pharmacological


**Main Results:**



**Sustained Benefits:  
Improved Angina and  
Quality of Life**

# Cas clinique: Patient de 59 ans angor d'effort

## Coroscanner pont myocardique



Base



Acétylcholine 100 mcg



Nitrés



# Cas clinique: Patient de 59 ans angor d'effort Coroscanner pont myocardique



Evaluation de la microcirculation

# Cas clinique: Patient de 59 ans angor d'effort

## Coroscanner pont myocardique



**Conclusion angor sur:**

**Spasme coronaire IVA**

**Trouble de la microcirculation IVA**

**Pont myocardique (FFR 0,83)**


**Traitement de sortie:**

**Tildiem 60 mg x 3**

**Trinipatch 10 mg**



# Perspectives thérapeutiques



# Conclusion microcirculation en 2022

- **INOCA est fréquent 40-50% des angors sans atteinte coronaire**
- **Majorité de femme**
- **Plusieurs méthodes de mesure (plus reproductible, moins invasive)**
- **Réel impact thérapeutique**
- **Nouvelles thérapeutiques à venir**